SMT201300013B - Lixisenatide come terapia aggiuntiva a insulina glargina e metformina per il trattamento del diabetedi tipo 2 - Google Patents

Lixisenatide come terapia aggiuntiva a insulina glargina e metformina per il trattamento del diabetedi tipo 2

Info

Publication number
SMT201300013B
SMT201300013B SM201300013T SM201300013T SMT201300013B SM T201300013 B SMT201300013 B SM T201300013B SM 201300013 T SM201300013 T SM 201300013T SM 201300013 T SM201300013 T SM 201300013T SM T201300013 B SMT201300013 B SM T201300013B
Authority
SM
San Marino
Prior art keywords
lixisenatide
metformin
diabetes
treatment
type
Prior art date
Application number
SM201300013T
Other languages
English (en)
Italian (it)
Inventor
Louise Silvestre
Elisabeth Souhami
Xiaodan Wei
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41800749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201300013(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of SMT201300013B publication Critical patent/SMT201300013B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM201300013T 2009-11-13 2013-01-30 Lixisenatide come terapia aggiuntiva a insulina glargina e metformina per il trattamento del diabetedi tipo 2 SMT201300013B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09175877.1A EP2329848B2 (fr) 2009-11-13 2009-11-13 Lixisénatide en tant que traitement d'appoint à l'insuline glargine et à la metformine dans le diabète de type 2

Publications (1)

Publication Number Publication Date
SMT201300013B true SMT201300013B (it) 2013-03-08

Family

ID=41800749

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201300013T SMT201300013B (it) 2009-11-13 2013-01-30 Lixisenatide come terapia aggiuntiva a insulina glargina e metformina per il trattamento del diabetedi tipo 2

Country Status (11)

Country Link
EP (1) EP2329848B2 (fr)
CY (1) CY1113755T1 (fr)
DK (1) DK2329848T4 (fr)
ES (1) ES2398012T5 (fr)
HR (1) HRP20121029T4 (fr)
ME (1) ME01546B (fr)
PL (1) PL2329848T5 (fr)
PT (1) PT2329848E (fr)
RS (1) RS52629B2 (fr)
SI (1) SI2329848T2 (fr)
SM (1) SMT201300013B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56632B1 (sr) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
JP6199186B2 (ja) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
AU2012213435B2 (en) * 2011-02-02 2017-03-30 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) * 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US20130296236A1 (en) * 2011-10-28 2013-11-07 Louise SILVESTRE Treatment protocol of diabetes type 2
JP6457484B2 (ja) 2013-04-03 2019-01-23 サノフイＳａｎｏｆｉ インスリンの長時間作用型製剤による糖尿病の治療
KR102231074B1 (ko) * 2013-06-17 2021-03-22 사노피-아벤티스 도이칠란트 게엠베하 인슐린 글라진／릭시세나티드 고정비 제형
MX2017007699A (es) 2014-12-12 2017-09-18 Sanofi Aventis Deutschland Formulacion de proporcion fija de insulina glargina/lixisenatida.
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (fr) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides abaissant le taux de glucose sanguin

Also Published As

Publication number Publication date
PL2329848T3 (pl) 2013-05-31
EP2329848B1 (fr) 2012-10-24
ES2398012T3 (es) 2013-03-13
RS52629B2 (sr) 2019-11-29
DK2329848T3 (da) 2013-02-04
SI2329848T2 (sl) 2019-10-30
HRP20121029T4 (hr) 2019-10-18
SI2329848T1 (sl) 2013-02-28
EP2329848A1 (fr) 2011-06-08
EP2329848B2 (fr) 2019-06-19
ME01546B (me) 2014-04-20
HRP20121029T1 (hr) 2013-01-31
CY1113755T1 (el) 2016-07-27
PT2329848E (pt) 2013-01-23
ES2398012T5 (es) 2020-02-26
RS52629B (en) 2013-06-28
PL2329848T5 (pl) 2019-12-31
DK2329848T4 (da) 2019-09-09

Similar Documents

Publication Publication Date Title
SMT201300013B (it) Lixisenatide come terapia aggiuntiva a insulina glargina e metformina per il trattamento del diabetedi tipo 2
NL300883I2 (nl) insulin glargine/lixisenatide
HRP20170209T1 (hr) Liksisenatid kao dodatna terapija uz bazalni inzulin kod dijabetesa tipa 2
PT2324853E (pt) Lixisenatida como adjuvante da metformina no tratamento de diabetes do tipo 2
HK1256637A1 (zh) 用於治療或預防心力衰竭的神經調節蛋白或其亞序列的治療性施劑
SI2611458T1 (sl) Uporaba AVE0010 za izdelavo zdravila za zdravljenje sladkorne bolezni tipa 2
PL2707017T3 (pl) Liksisenatyd i metformina do leczenia cukrzycy typu 2
IL219945A (en) 1-GLP history with dual transduction and use of it to prepare a drug for the treatment of diabetes
IL212903A0 (en) Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy comprising a dpp-iv inhibitor
IL209887A0 (en) Treatment for diabetes in patients inappropriate for metformin therapy
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
GB0919603D0 (en) Use of thymosin beta-4 for treatment of type II diabetes
SG10201601210YA (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
TH0901003547A (th) การรักษาสำหรับโรคเบาหวานในคนไข้ที่ไม่เหมาะสำหรับการรักษาด้วยเมทฟอร์มิน
BR112013031487A2 (pt) combinação sinérgica para o tratamento de diabetes mellitus tipo 2
TH0901004644A (th) สารประกอบสไปโร-ออกซินดอล และการใช้สารเป็นยารักษาโรค
GB0904178D0 (en) General cure to diseases idea 3
TH0901003991A (th) สารประกอบที่เชื่อมต่อกับซัลเฟอร์สำหรับการบำบัดโรค และความผิดปกติที่เกี่ยวกับตา